ClinicalTrials.gg
CompletedNCT00525265Updated Dec 25, 2013Results posted

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

A Phase 3 interventional study of OPC-41061(Tolvaptan) and Placebo in Cardiac Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 2 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-12-25.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

To investigate the pharmacokinetics, pharmacodynamics (urine volume and fluid intake), efficacy(body weight, pulmonary congestion and other congestions including cardiothoracic ratio) and safety of 7-day repeated oral administration of OPC-41061 at 7.5 mg or 15 mg in congestive heart failure (cardiac edema) patients with extracellular volume expansion despite the use of a diuretic.

02

Conditions studied

  • Cardiac Edema

Keywords

  • Vasopressin antagonist
  • Cardiac Edema
  • Diuretics
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with cardiac edema receiving diuretic treatments 7 days prior to the start of treatment.
  2. Subjects able to receive a daily regular dosage of furosemide at 40-mg to 80-mg from the observation period until the end-of-treatment examination.
  3. CHF patients with lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion.
  4. Male or female subjects between the age of 20 and 85, inclusive.
  5. Subjects able to stay at the study site from the day before the start of the run-in observation period until completion of post-dosing examination 2.
  6. Subjects capable of giving to participate in the study of their own free will.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with heart failure with markedly fluctuating symptoms.
  2. Subjects with an assisted circulation device.
  3. Subjects with any of the following complications or symptoms:(1)Suspected decrease in circulatory blood flow,(2)Hypertrophic cardiomyopathy (other than dilated phase),(3)Cardiac valve disease with significant heart valve stenosis,(4)Hepatic coma.
  4. Subjects who develop acute myocardial infarction within 30 days prior to the screening examination.
  5. Subjects with well-defined diagnosis of active myocarditis or amyloid cardiomyopathy.
  6. Subjects with any of the following complications or symptoms:(1)Diabetes mellitus with poorly controlled blood glucose,(2)Anuria,(3)Urination impaired due to urinary tract stricture,urinary calculus,tumor in urinary tract,or other cause.
  7. Subjects with a history of any of the following diseases:(1)Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination in patients without an implanted defibrillator,(2)Cerebrovascular disorder within 6 months prior to the screening examination (other than asymptomatic cerebral infarction),(3) or idiosyncratic reaction to benzazepine derivatives.
  8. Subjects who are morbidly obese ( exceeding 35).
  9. Subjects with systolic blood pressure in the decubitus position below 90 mmHg.
  10. Subjects with any of the following abnormal laboratory values:(1)Total > 3.0 mg/dL,(2) serum creatinine > 3.0 mg/dL,(3)serum sodium > 147 mEq/L,(4)serum potassium > 5.5 mEq/L.
  11. Subjects who are unable to take oral medication.
  12. Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant.
  13. Subjects who received any drug other than OPC-41061 within 30 days prior to the screening examination.
  14. Subjects who previously participated in this or any other study of OPC-41061 and received OPC-41061.
  15. Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    1

    OPC-41061

    Drug: OPC-41061(Tolvaptan)

  • Placebo comparator
    2

    placebo

    Drug: Placebo

Interventions

  • Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.

  • DrugPlacebo

    Subjects will be orally administered placebo once daily after breakfast for seven days.

06

What researchers measure

Primary outcomes

  1. Body Weight

    The body weight change from baseline at the time of final trial drug administration

    Time frame: Baseline, at the time of final trial drug administration

07

Results

Posted Dec 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061 7.5 mgOPC-41061 15 mg
Started1010
Completed910
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryBody Weight

The body weight change from baseline at the time of final trial drug administration

Time frame:
Baseline, at the time of final trial drug administration
Reported as:
Mean · Kg
Body Weight
KgOPC-41061 7.5 mgOPC-41061 15 mg
Body Weight-1.68 ± 1.83-2.14 ± 1.45

Adverse events

Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-41061 7.5 mg—0/10 (0%)10/10 (100%)
OPC-41061 15 mg—1/10 (10%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventOPC-41061 7.5 mgOPC-41061 15 mg
Ventricular TachycardiaCardiac disorders0/101/10
Most frequent other events
Showing 10 of 34
Most frequent other events
EventOPC-41061 7.5 mgOPC-41061 15 mg
Blood Urea IncreasedInvestigations2/105/10
ThirstGeneral disorders4/104/10
Blood Creatinine IncreasedInvestigations2/104/10
PyrexiaGeneral disorders2/101/10
NasopharyngitisInfections and infestations2/100/10
PharyngitisInfections and infestations2/100/10
Back PainMusculoskeletal and connective tissue disorders2/100/10
PollakiuriaRenal and urinary disorders1/102/10
ConstipationGastrointestinal disorders0/101/10
Epigastric DiscomfortGastrointestinal disorders0/101/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OPC-41061 7.5 mgOPC-41061 15 mgTotal
<=18 years000
Between 18 and 65 years448
>=65 years6612
Age Continuous
Age Continuous(years)OPC-41061 7.5 mgOPC-41061 15 mgTotal
Mean69.1 ± 13.666.8 ± 10.268.0 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061 7.5 mgOPC-41061 15 mgTotal
Female628
Male4812
Region of Enrollment
Region of Enrollment(participants)OPC-41061 7.5 mgOPC-41061 15 mgTotal
Japan101020
08

Study locations

2 sites
  • Kanto region, Japan
  • Kyushu region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2007
First posted
Sep 5, 2007
Start
Sep 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Dec 25, 2013
Last update
Dec 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00525265
Responsible party
Sponsor
First posted
Sep 5, 2007
Start date
Sep 2007
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Dec 25, 2013
Last update
Dec 25, 2013

Study contacts

Katsuhisa Saito
study director · Division of New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion